{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:23:57Z","timestamp":1778199837755,"version":"3.51.4"},"reference-count":28,"publisher":"Japanese Society of Internal Medicine","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,12,1]]},"DOI":"10.2169\/internalmedicine.5327-25","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T18:08:23Z","timestamp":1747850903000},"page":"3395-3402","source":"Crossref","is-referenced-by-count":1,"title":["Blue Toe Syndrome Responding to Direct Hemoadsorption Therapy with the Rheocarna&lt;sup&gt;\u00ae&lt;\/sup&gt; Device"],"prefix":"10.2169","volume":"64","author":[{"given":"Junichiro","family":"Nishiyama","sequence":"first","affiliation":[{"name":"Seisyukai Clinic, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Aoyagi","sequence":"additional","affiliation":[{"name":"Renal Center, Seisyukai Clinic, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyoshi","family":"Tsuru","sequence":"additional","affiliation":[{"name":"Renal Center, Seisyukai Clinic, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayaka","family":"Tsubaki","sequence":"additional","affiliation":[{"name":"Renal Center, Seisyukai Clinic, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sae","family":"Imamura","sequence":"additional","affiliation":[{"name":"Renal Center, Seisyukai Clinic, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuma","family":"Nagahama","sequence":"additional","affiliation":[{"name":"Renal Center, Seisyukai Clinic, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Elinav E, Chajek-Shaul T, Stern M. Improvement in cholesterol emboli syndrome after iloprost therapy. BMJ 324: 268-269, 2002.","DOI":"10.1136\/bmj.324.7332.268"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Minatohara K. Renal failure associated with blue toe syndrome: effective treatment with intravenous prostaglandin E-1. Acta Derm Venereol 86: 364-365, 2006.","DOI":"10.2340\/00015555-0091"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Tunick PA, Nayar AC, Goodkin GM, et al.; NYU Atheroma Group. Effect of treatment on the incidence of stroke and other emboli in 519 patients with severe thoracic aortic plaque. Am J Cardiol 90: 1320-1325, 2002.","DOI":"10.1016\/S0002-9149(02)02870-9"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Mann SJ, Sos TA. Treatment of atheroembolization with corticosteroids. Am J Hypertens 14: 831-834, 2001.","DOI":"10.1016\/S0895-7061(01)02183-5"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Koga J, Ohno M, Okamoto K, et al. Cholesterol embolization treated with corticosteroids - two case reports. Angiology 56: 497-501, 2005.","DOI":"10.1177\/000331970505600420"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Hasegawa M, Kawashima S, Shikano M, et al. The evaluation of corticosteroid therapy in conjunction with plasma exchange in the treatment of renal cholesterol embolic disease. A report of 5 cases. Am J Nephrol 20: 263-267, 2000.","DOI":"10.1159\/000013598"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Ishiyama K, Sato T. Efficacy of LDL apheresis for the treatment of cholesterol crystal embolism: a prospective, controlled study. Ther Apher Dial 26: 456-464, 2022.","DOI":"10.1111\/1744-9987.13706"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ishiyama K, Sato T, Yamaguchi T, Taguma Y. Efficacy of low-density lipoprotein apheresis combined with corticosteroids for cholesterol crystal embolism. Clin Exp Nephrol 21: 228-235, 2017.","DOI":"10.1007\/s10157-016-1272-x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Hasegawa M, Sugiyama S. Apheresis in the treatment of cholesterol embolic disease. Ther Apher Dial 7: 435-438, 2003.","DOI":"10.1046\/j.1526-0968.2003.00081.x"},{"key":"10","unstructured":"10. Hidaka S, Kobayashi S. [Rheocarna<sup>\u00ae<\/sup>: A novel apheresis device for the treatment of peripheral arteriosclerosis obliterans in dialysis patients]. Jinko Zoki (Artificial Organs) 51: 55-61, 2022 (in Japanese)."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Satake A, Tokuda T, Niwa T, et al. Chronic clinical findings after rheocarna<sup>\u00ae<\/sup> therapy in a chronic limb-threatening ischemia patient with inframalleolar lesions. Intern Med 63: 2293-2296, 2024.","DOI":"10.2169\/internalmedicine.2917-23"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kobayashi S, Furukawa M, Ichioka S, et al. A novel low-density lipoprotein\/fibrinogen apheresis method for chronic limb-threatening ischemia in patients with poor options for revascularization: a multicenter, single-arm clinical trial. Ther Apher Dial 27: 361-369, 2023.","DOI":"10.1111\/1744-9987.13915"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Karmody AM, Powers SR, Monaco VJ, Leather RP.  &quot;Blue toe&quot; syndrome. An indication for limb salvage surgery. Arch Surg 111: 1263-1268, 1976.","DOI":"10.1001\/archsurg.1976.01360290097015"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Kronzon I, Saric M. Cholesterol embolization syndrome. Circulation 122: 631-641, 2010.","DOI":"10.1161\/CIRCULATIONAHA.109.886465"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Igarashi Y, Akimoto T, Kobayashi T, et al. Performing anticoagulation: a puzzling case of cholesterol embolization syndrome. Clin Med Insights Case Rep 10: 1179547616684649, 2017.","DOI":"10.1177\/1179547616684649"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Fukumoto Y, Tsutsui H, Tsuchihashi M, Masumoto A, Takeshita A; Cholesterol Embolism Study (CHEST) Investigators. The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study. J Am Coll Cardiol 42: 211-216, 2003.","DOI":"10.1016\/S0735-1097(03)00579-5"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Mochida Y, Ohtake T, Ishioka K, et al. Association between eosinophilia and renal prognosis in patients with pathologically proven cholesterol crystal embolism. Clin Exp Nephrol 24: 680-687, 2020.","DOI":"10.1007\/s10157-020-01886-9"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Tunick PA, Krinsky GA, Lee VS, Kronzon I. Diagnostic imaging of thoracic aortic atherosclerosis. AJR Am J Roentgenol 174: 1119-1125, 2000.","DOI":"10.2214\/ajr.174.4.1741119"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Ozkok A. Cholesterol-embolization syndrome: current perspectives. Vasc Health Risk Manag 15: 209-220, 2019.","DOI":"10.2147\/VHRM.S175150"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Zhao D, Han C, Mammadova-Bach E, et al. Inhibition of complement factor C5a or C5aR for cholesterol crystal embolism-related vascular thrombosis with microvascular injury and its consequences. Kidney Int 106: 819-825, 2024.","DOI":"10.1016\/j.kint.2024.07.020"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Satake A, Tokuda T, Ohashi H, Nakano Y, Kodama A, Amano T. Rheocarna effectively treats oral medicinal therapy-resistant cutaneous symptoms and renal failure induced by cholesterol crystal embolism. Clin Case Rep 12: e9608, 2024.","DOI":"10.1002\/ccr3.9608"},{"key":"22","unstructured":"22. Gomyo M, Ishizuka S, Takayama K. A case of gangrene of the feet due to blue toe syndrome successfully treated with Leocana<sup>\u00ae<\/sup>. Rinsyo Hifuka (Jpn J Clin Dermatol) 78: 289-294, 2024 (in Japanese)."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Kobayashi S. Applications of LDL-apheresis in nephrology. Clin Exp Nephrol 12: 9-15, 2008.","DOI":"10.1007\/s10157-007-0003-8"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Handa T, Fujii M, Ando M, et al. Correlation between bradykinin concentration and blood pressure during Rheocarna therapy: a single-center case series. Ther Apher Dial 28: 453-459, 2024.","DOI":"10.1111\/1744-9987.14105"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Kojima S, Ogi M, Sugi T, Matsumoto Y, Yoshitomi Y, Kuramochi M. Changes in plasma levels of nitric oxide derivative during low-density lipoprotein apheresis. Ther Apher 1: 356-361, 1997.","DOI":"10.1111\/j.1744-9987.1997.tb00055.x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Kizaki Y, Ueki Y, Yoshida K, et al. Does the production of nitric oxide contribute to the early improvement after a single low-density lipoprotein apheresis in patients with peripheral arterial obstructive disease? Blood Coagul Fibrinolysis 10: 341-349, 1999.","DOI":"10.1097\/00001721-199909000-00004"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Tsurumi-Ikeya Y, Tamura K, Azuma K, et al. Sustained inhibition of oxidized low-density lipoprotein is involved in the long-term therapeutic effects of apheresis in dialysis patients. Arterioscler Thromb Vasc Biol 30: 1058-1065, 2010.","DOI":"10.1161\/ATVBAHA.109.200212"},{"key":"28","doi-asserted-by":"publisher","unstructured":"28. Mii S, Mori A, Sakata H, Nakayama M, Tsuruta H. LDL apheresis for arteriosclerosis obliterans with occluded bypass graft: change in prostacyclin and effect on ischemic symptoms. Angiology 49: 175-180, 1998.","DOI":"10.1177\/000331979804900302"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/23\/64_5327-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T03:27:48Z","timestamp":1764991668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/23\/64_5327-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":28,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5327-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"article-number":"5327-25"}}